Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formulary
Question
Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formulary
Direct answer
Broad PBM formulary coverage for oral obesity drug Foundayo expands addressable patient volume and supports long-term revenue diversification for LLY. — bullish pressure on LLY via oral metabolic drug commercial access and volume expansion.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-18
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formulary”, revision 1, evidence through 2026-09-18. https://marketontology.com/catalysts/2026-09-18/eli-lilly-generates-27-7b-in-1h-glp-1-sales-as-foundayo-gains-pbm-formulary-bb9fe4
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| LLY | ▲Bull | 1–3 months | oral metabolic drug commercial access and volume expansion | 71 |
Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formulary
Broad PBM formulary coverage for oral obesity drug Foundayo expands addressable patient volume and supports long-term revenue diversification for LLY. — bullish pressure on LLY via oral metabolic drug commercial access and volume expansion.
Recorded $27.7B in 1H GLP-1 sales and secured major PBM coverage for Foundayo.
- SourceRecorded $27.7B in 1H GLP-1 sales and secured major PBM coverage for Foundayo.
- TransmissionBroad PBM formulary coverage for oral obesity drug Foundayo expands addressable patient volume and supports long-term revenue diversification for LLY.
- SummaryEli Lilly posted $27.7 billion in first-half sales across Mounjaro and Zepbound. Oral obesity treatment Foundayo secured formulary placement with major PBMs. Non-core therapeutic lines expanded 121% in Q2, diversifying revenue streams.
- LLYDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Sector rotation or peer guidance may override single-name reaction
- LLY closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- LLY price vs. pre-event level
- LLY volume vs. 20-day average
- Sector ETF read-through
- Options implied volatility crush
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious? · financial_news · 2026-09-17
Related catalysts
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY
- 2026-10-19Viking Therapeutics Raises $575 Million to Fund Phase 3 Obesity TrialsLLY VKTX
- 2026-10-19Viking Therapeutics Raises $575 Million to Fund Phase 3 Obesity TrialsLLY VKTX
- 2026-10-19Viking raises $575 million to fund obesity trials through 2028LLY NVO VKTX
- 2026-10-19Viking Therapeutics Raises $575M in Equity and Convertibles for Phase 3 TrialsLLY VKTX
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY SPY
- 2026-10-19Viking raises $575 million to fund obesity pipeline trialsLLY VKTX
- 2026-10-19Viking financing keeps obesity trial runway open through 2028LLY VKTX
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.